Cal. Code Regs. tit. 16, § 1746
(b) Protocol for Pharmacists Furnishing Emergency Contraception (EC).
(3) Procedure: When a patient requests emergency contraception, the pharmacist will ask and communicate the following:
• Are you allergic to any medications?
• Timing is an essential element of the product's effectiveness. EC should be taken as soon as possible after unprotected intercourse. Treatment may be initiated up to five days (120 hours) after unprotected intercourse.
EC use will not interfere with an established or implanted pregnancy.
If more than 72 hours have elapsed since unprotected intercourse, the use of ellaTM (ulipristal) may be more effective than levonorgestrel. For other options for EC, consult with your health care provider.
Please follow up with your health care provider after the use of EC.
(4) The pharmacist shall provide a fact sheet and review any questions the patient may have regarding EC. In addition, the pharmacist shall collect the information required for a patient medication record required by Section 1707.1 of Title 16 of the California Code of Regulations.
Fact Sheet: The pharmacist will provide the patient with a copy of the current EC fact sheet approved by the Board of Pharmacy as required by Business and Professions Code Section 4052.3(e).
(11) Medications Used for Emergency Contraception
Dedicated Approved Products for Emergency Contraception
Brand
Dose
Ethinyl Estradiol per dose (mcg)
One Tablet Regimens
Plan BTM One-Step
1 tablet
0
1.5mg levonorgestrel
ellaTM
1 tablet
0
30mg ulipristal
Levonorgestrel
1 tablet
0
1.5mg levonorgestrel
Two Tablet Regimens
Next ChoiceTM
2 tablets at once (1.5mg total dose) or 1 tablet (0.75mg) followed by 1 tablet (0.75mg) 12 hours later
0
Each tablet is 0.75 mg levonorgestrel
Levonorgestrel
2 tablets at once (1.5mg total dose) or 1 tablet (0.75mg) followed by 1 tablet (0.75mg) 12 hours later
0
Each tablet is 0.75 mg levonorgestrel
Oral Contraceptive Pills
Brand
Tablets per Dose
Ethinyl Estradiol
Levonorgestrel
(two doses 12 hours apart*)
per dose (mcg)
per dose (mg)*
Alesse
5 pink tablets
100
0.50
Aviane
5 orange tablets
100
0.50
Levlen
4 light-orange tablets
120
0.60
Levlite
5 pink tablets
100
0.50
Levora
4 white tablets
120
0.60
Lo/Ovral
4 white tablets
120
0.50
Low-Ogestrel
4 white tablets
120
0.60
Nordette
4 light-orange tablets
120
0.60
Ogestrel
2 white tablets
100
0.50
Ovral
2 white tablets
100
0.50
Tri-Levlen
4 yellow tablets
100
0.50
Triphasil
4 yellow tablets
120
0.50
Trivora
4 pink tablets
120
0.50
Ovrette
20 yellow tablets
0
0.75
* The progestin in Ovral, Lo/Ovral, and Ovrette is norgestrel, which contains two isomers, only one of which (levonorgestrel) is bioactive; the amount of norgestrel in each dose is twice the amount of levonorgestrel.
In addition to the products specified in this paragraph, generic equivalent products may be furnished. Estrogen containing regimens are not preferred and should be used only when the other options are not available.
(12) Anti-nausea Treatment Options for use with Emergency Contraception
Non-Prescription Drugs
Dose
Timing of Administration
Meclizine hydrochloride (Dramamine II, Bonine)
One or two 25 mg tablets
1 hour before first EC dose; Repeat if needed in 24 hours
Diphenhydramine hydrochloride (Benadryl)
One or two 25 mg tablets or capsules
1 hour before first EC dose; repeat as needed every 4-6 hours
Dimenhydrinate (Dramamine)
One or two 50 mg tablets or 4-8 teaspoons liquid
30 minutes to 1 hour before first EC dose; repeat as needed every 4-6 hours
Cyclizine hydrochloride (Marezine)
One 50 mg tablet
30 minutes before first EC dose; repeat as needed every 4-6 hours
Note: Authority cited: Section 4005, Business and Professions Code. Reference: Sections 4052 and 4052.3, Business and Professions Code.
1. New section filed 11-2-2004; operative 12-2-2004 (Register 2004, No. 45). For prior history, see Register 80, No. 8.
2. Change without regulatory effect amending subsections (a) and (b)(1) and amending Note filed 12-18-2007 pursuant to section 100, title 1, California Code of Regulations (Register 2007, No. 51).
3. Amendment filed 3-13-2013; operative 7-1-2013 (Register 2013, No. 11).